Showing 191-200 of 4063 results for "".
Giving a Nod to Nodular Episcleritis
https://modernod.com/topics/corneaanterior-segment/giving-a-nod-to-nodular-episcleritis/38655/Systemic workup may be warranted to rule out a more serious condition.A Collaborative Approach to iStent Inject Implementation
https://modernod.com/mod-issues/2019-may/a-collaborative-approach-to-istent-inject-implementation/39064/The only MIGS device with two multidirectional stents has the potential to simplify the management of your patient’s glaucoma.Improving the Standard of Care in AMD
https://modernod.com/articles/improving-the-standard-of-care-in-amd/improving-the-standard-of-care-in-amd-2/38282/When the Diagnosis Is Not Glaucoma
https://modernod.com/topics/glaucoma/when-the-diagnosis-is-not-glaucoma/38072/Know the masqueraders.Glucagon-Like Peptide 1 Receptor Agonists and the Eye
https://modernod.com/topics/nutritionpharmaceuticals/glucagon-like-peptide-1-receptor-agonists-and-the-eye/38808/These drugs offer a promising outlook as transformative therapies in glycemic control, weight management, and more, but what effect do they have on our patients’ ocular health?iStent Inject: New MIGS on the Block
https://modernod.com/mod-issues/2019-apr/istent-inject-new-migs-on-the-block/39059/Advanced technology for seamless comanagement and the potential to simplify glaucoma management.Legal Liability Issues in Keratoconus
https://modernod.com/topics/corneaanterior-segment/legal-liability-issues-in-keratoconus/38652/Provide care to avoid liability.Ocular Effects of Pituitary Tumor
https://modernod.com/topics/imagingdiagnostics/ocular-effects-of-pituitary-tumor/38974/Visual symptoms may be the first clues that a patient has developed this pituitary adenoma.Highlights From MOD Live 2024 in Nashville
https://modernod.com/podcasts/the-mod-pod/highlights-from-mod-live-2024-in-nashville/36865/In this special episode of The MOD Pod, Cecelia Koetting, OD, FAAO, Dipl ABO, interviews a diverse group of attendees from MOD Live 2024. She speaks with program chairs, faculty, newcomers, and returning attendees, capturing a wide range of perspectives.2024 Year in Review — Part 1
https://modernod.com/podcasts/eyewire-news-the-podcast/2024-year-in-review-part-1/37064/In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout